Search

Displaying results 1691 - 1700 of 8410 in total
  1. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    [A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD … [A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSynonyms: (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
  2. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  3. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399]

  4. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Categories: Purinergic P1 Receptor Agonists
  5. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination … being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an

  6. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: Triveen-Duo DHA, PR Natal 430
  7. Drug

    Arotinoid acid

    go.drugbank.com/drugs/DB02877
    Experimental

    Arotinoid acid is a retinoic acid analog which acts as a selective RAR agonist.

  8. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.

  9. Drug

    Foscarnet

    go.drugbank.com/drugs/DB00529
    ApprovedInvestigational

    An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

  10. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.